Finally, it has been proposed that the onset of steatosis in patients treated with 5-FU could be attributed to the individual expression pattern of specific genes linked with 5-FU metabolism, in particular to decreased levels of dihydropyrimidine dehydrogenase (DPD) [130]. The gene discussed is DPYD; the disease is steatosis.